IMO 9200

Drug Profile

IMO 9200

Alternative Names: IMO-9200

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator Idera Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Immunomodulators; Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists; Toll-like receptor 9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders
  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 28 Nov 2016 IMO 9200 licensed to Vivelix Pharmaceuticals worldwide
  • 18 May 2015 Adverse events data from a phase I trial in Autoimmune diseases and pharmacodynamic data from a preclinical trial in Inflammatory bowel disease released by Idera
  • 17 May 2015 Preclinical trials in Inflammatory bowel disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top